

Drugs and Diagnostics for Hematological Disorders: Global Markets

Market Research Report | 2024-07-02 | 133 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope

This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs. The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies. The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.

Report Includes

- 49 data tables and 44 additional tables
- An overview of the current and future global markets for drugs and diagnostics for hematological disorders
- Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
- Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
- Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
- A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
- Review of technological developments, product introductions, and other recent industry activity of the major players

- Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
- An analysis of recent patents
- A look at the competitive landscape, including companies' market shares, M&A activity and venture funding
- Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Executive Summary

Summary:

The global market for drugs and diagnostics for hematological disorders is expected to grow from \$131.2 billion in 2024 and is projected to reach \$189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

PESTEL Analysis

Political

Economic

Social

Technological

Environmental

Legal

Porter's Five Forces Analysis

Bargaining Power of Buyers

Bargaining Power of Suppliers

Potential of New Entrants

Threat of Substitutes

Competition in the Industry

Supply Chain and Logistics for Hematological Instruments

Chapter 3 Market Dynamics

Market Drivers

Incidence of Blood Disorders

Rising Use of Automation

Diagnosis of Hematology Disorders

Increasing Government and Private Funding for Treatment

Market Restraints

High Cost of Instruments

High Cost of Treatment

Reimbursement Challenges for Physicians

Market Opportunities

Scotts International, EU Vat number: PL 6772247784

Rising Health Awareness

Emerging Economies

Chapter 4 Patent Landscape and Current Developments in Drugs

Patent Landscape

New Approvals

Chapter 5 Emerging Technologies and Developments

Overview

Emerging Technologies

Al-Assisted Diagnosis

Next-Generation Sequencing (NGS)

Microfluidics and Lab-on-a-Chip Devices

Gene Therapies

Immunotherapies

Clinical Trials

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown

Segmentation by Market

Hematological Disorders Diagnostics Market

Hematological Disorders Diagnostic Market, By Product Type

Hematological Disorders Diagnostic Market, By End User

Hematology Drug Market

Hematology Drug Market, By Drug Type

Geographic Breakdown

North America

Europe

Asia-Pacific

Rest of the World

Chapter 7 Competitive Intelligence

Leading Companies

Hematological Disorder Diagnostics

Hematological Disorder Drugs

New Developers of Drugs for Rare Hematology Disorders

Chapter 8 Appendix

Methodology

Sources

Abbreviations

Company Profiles

ABBOTT

AMGEN INC.

BIO-RAD LABORATORIES INC.

BRISTOL MYERS SQUIBB CO.

DANAHER CORP.

F. HOFFMANN-LA ROCHE LTD.

NOVARTIS AG

SANOFI

SYSMEX CORP.

TAKEDA PHARMACEUTICAL CO. LTD.

Scotts International, EU Vat number: PL 6772247784



To place an Order with Scotts International:

Drugs and Diagnostics for Hematological Disorders: Global Markets

Market Research Report | 2024-07-02 | 133 pages | BCC Research

- Print this form				
	elevant blank fields and sign			
] - Send as a scan	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$5500.00
	2-5 Users License			\$6600.00
	Site License			\$7920.00
	Enterprise License			\$9504.00
				VAT
				Total
	rant license option. For any questions plant 23% for Polich based companies, indi-			
** VAT will be added	vant license option. For any questions pl at 23% for Polish based companies, indi	viduals and EU based		
]** VAT will be added ∂				
		viduals and EU based		
]** VAT will be added a		viduals and EU based Phone*		
]** VAT will be added a Email* First Name*		viduals and EU based Phone*	companies who are unable to pro	
]** VAT will be added a Email* First Name* Tob title* Company Name*		viduals and EU based Phone* Last Name*	companies who are unable to pro	
** VAT will be added a Email* First Name* lob title*		Phone* Last Name* EU Vat / Tax ID	companies who are unable to pro	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784